Extended 5-Year Follow-Up Results of a Phase 1b Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

PURPOSE: To report the 5-year overall survival (OS) landmark and the long-term safety profile of vemurafenib plus cobimetinib (BRAF plus MEK inhibition, respectively) in the BRIM7 study. PATIENTS AND METHODS: This phase 1b, dose-finding and expansion study evaluated combination treatment with vemura...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Ribas, Antoni, Daud, Adil, Pavlick, Anna C., Gonzalez, Rene, Lewis, Karl D., Hamid, Omid, Gajewski, Thomas F., Puzanov, Igor, Wongchenko, Matthew, Rooney, Isabelle, Hsu, Jessie J., Yan, Yibing, Park, Erica, McArthur, Grant A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6942621/
https://ncbi.nlm.nih.gov/pubmed/31732523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-4180
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados